Last reviewed · How we verify
Anestan (HALOTHANE)
Halothane (Anestan) is a marketed general anesthetic that operates by enhancing the inhibitory effects of GABA, currently holding a position in a competitive market dominated by off-patent alternatives such as enflurane, isoflurane, desflurane, and sevoflurane. A key strength of Halothane is its well-established mechanism of action, which has been widely recognized since its introduction. The primary risk facing Halothane is the strong competition from multiple generic alternatives within the same class, which may limit its market share and revenue potential.
At a glance
| Generic name | HALOTHANE |
|---|---|
| Drug class | halothane |
| Target | GABA-A receptor; anion channel |
| Modality | Small molecule |
| Therapeutic area | Neuroscience |
| Phase | FDA-approved |
| First approval | 1958 |
Approved indications
- General anesthesia
Common side effects
Drug interactions
- ephedrine
- labetalol
Key clinical trials
- Population at Risk of Malignant Hyperthermia: Ambispective Cohort.
- Opioid Free Anesthesia in Maxillofacial Surgery (NA)
- Malignant Hyperthermia Registry and Genetic Testing
- Vasodilation Effect of Inhalational Anesthetics (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Anestan CI brief — competitive landscape report
- Anestan updates RSS · CI watch RSS